Embark Biotech ApS is an early-stage biotech company focused on developing novel treatments for diseases with clear unmet needs within cardiometabolic and hyperphagic (i.e. food-craving) indications. Our first pipeline program focuses on engineering novel biologics that dually target fat tissue and the central nervous system (CNS) through an exciting, new mode-of-action (MoA). The communication between our fat tissue and brain is one of the most powerful, yet therapeutically under-targeted, axes in the regulation of appetite, energy expenditure, and overall cardiometabolic health. We uncovered a novel signaling pathway in the fat tissue-brain axis that both increases calorie-burning in the periphery and suppresses appetite through conserved feeding centers in the CNS. Using advanced peptide chemistry, Embark has generated a series of highly selective, long-acting agonists (compatible with once weekly administration in humans) that leverage this physiological program for potential pharmacotherapeutic gain. Backed by significant human genetic associations to metabolic health and validation in aged and obese nonhuman primates, Embark now seeks to evaluate this novel MoA in clinical phase I (SAD and MAD) and phase II (proof-of-concept) studies. Given the profoundly heightened efficacy in hyperphagic rodent models and severely insulin resistant nonhuman primates, we believe our peptide agonists offer a unique opportunity to dramatically improve the quality-of-life for people living with obesity, type 2 diabetes, binge-eating disorder, and rare hyperphagic diseases.